EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcome of patients with undifferentiated embryonal sarcoma of the liver treated according to European soft tissue sarcoma protocols

Florent Guérin iD, Hélène Martelli, Timothy Rogers iD, Ilaria Zanetti, Sheila Terwisscha van Scheltinga, Federica De Corti, Gabriella Guillen Burrieza, Véronique Minard-Colin, Daniel Orbach iD, Max M van Noesel iD, Marie Karanian, Raquel Dávila Fajardo iD und 3 weitere

Pediatric Blood & Cancer · 2023-07 · 70 (7)

DOI: 10.1002/pbc.30374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 21.04.2023. Verfasst von Florent Guérin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Université Paris-Saclay, Assistance Publique Hôpitaux de Paris (AP-HP), Bicêtre Hospital, Le Kremlin Bicêtre, France. Hauptthemen laut MEDLINE: Sarcoma, Rhabdomyosarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To assess the outcomes of pediatric patients with undifferentiated embryonal sarcoma of the liver (UESL) and treatment including at least surgery and systemic chemotherapy.

Methods

This study included patients aged up to 21 years with a pathological diagnosis of UESL prospectively enrolled from 1995 to 2016 in three European trials focusing on the effects of surgical margins, preoperative chemotherapy, use of radiotherapy (RT), and chemotherapy.

Results

Out of 65 patients with a median age at diagnosis of 8.7 years (0.6–20.8), 15 had T2 tumors, and one had lymph node spread, 14 were Intergroup Rhabdomyosarcoma Study (IRS) I, nine IRS II, 38 IRS III, and four IRS IV. Twenty‐eight upfront surgeries resulted in five operative spillages and 11 infiltrated surgical margins, whereas 37 delayed surgeries resulted in no spillages ( p = .0119) and three infiltrated margins ( p = .0238). All patients received chemotherapy, including anthracyclines in 47. RT was administered in 15 patients. With a median follow‐up of 78.6 months, 5‐year overall and event‐free survivals (EFS) were 90.1% (95% confidence interval [CI]: 79.2–95.5) and 89.1% (95% CI: 78.4–94.6), respectively. Two out four local relapses had previous infiltrated margins and two out of three patients with metastatic relapses received reduced doses of alkylating agents. Infiltrated margins ( p = .1607), T2 stage ( p = .3870), use of RT ( p = .8731), and anthracycline‐based chemotherapy ( p = .1181) were not correlated with EFS.

Conclusions

Multimodal therapy improved the outcome of UESL. Neoadjuvant chemotherapy for pediatric patients increases the probability of complete surgical resection. The role of anthracyclines and RT for localized disease remains unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaRhabdomyosarcomaSoft Tissue NeoplasmsChildHumansAgedMargins of ExcisionAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalAnthracyclinesLiver

Stichwörter der Autor:innen

antineoplasic agentsliverpediatricsradiotherapysarcomasurgical procedures

Substanzen

Anthracyclines

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Université Paris-Saclay, Assistance Publique Hôpitaux de Paris (AP-HP), Bicêtre Hospital, Le Kremlin Bicêtre, France.
  • Department of Pediatric Surgery, University Hospitals Bristol and Weston NHS foundation trust, Bristol, UK.
  • Department of Women's and Children's Health, Hematology Oncology Division, University of Padova, Padua, Italy.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Women's and Children's Health, Pediatric Surgery Unit, University of Padova, Padua, Italy.
  • Department of Pediatric Surgery, Vall d'Hebron University Hospital, Barcelona, Spain.

ORCID-Profile: Florent Guérin, Timothy Rogers, Daniel Orbach, Max M van Noesel, Raquel Dávila Fajardo, Andrea Ferrari, Gianni Bisogno

Zitieren

APA

Guérin, F., Martelli, H., Rogers, T., Zanetti, I., van Scheltinga, S. T., De Corti, F., Burrieza, G. G., Minard-Colin, V., Orbach, D., van Noesel, M. M., Karanian, M., Fajardo, R. D., Merks, J. H. M., Ferrari, A., & Bisogno, G. (2023). Outcome of patients with undifferentiated embryonal sarcoma of the liver treated according to European soft tissue sarcoma protocols. Pediatric Blood & Cancer, 70(7). https://doi.org/10.1002/pbc.30374

Vancouver

Guérin F, Martelli H, Rogers T, Zanetti I, van Scheltinga ST, De Corti F, et al. Outcome of patients with undifferentiated embryonal sarcoma of the liver treated according to European soft tissue sarcoma protocols. Pediatric Blood & Cancer. 2023;70(7). doi:10.1002/pbc.30374

BibTeX
@article{Gurin2023,
  author = {Guérin, Florent and Martelli, Hélène and Rogers, Timothy and Zanetti, Ilaria and van Scheltinga, Sheila Terwisscha and De Corti, Federica and Burrieza, Gabriella Guillen and Minard-Colin, Véronique and Orbach, Daniel and van Noesel, Max M and Karanian, Marie and Fajardo, Raquel Dávila and Merks, Johannes H M and Ferrari, Andrea and Bisogno, Gianni},
  title = {Outcome of patients with undifferentiated embryonal sarcoma of the liver treated according to European soft tissue sarcoma protocols},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  volume = {70},
  number = {7},
  doi = {10.1002/pbc.30374}
}
Kostenlos starten →